Bayesian Power‐Based Sample Size Determination for Single‐Arm Clinical Trials With Time‐to‐Event Endpoints
Pharmaceutical Statistics · 2026
DOI: 10.1002/pst.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2026. Verfasst von Go Horiguchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Endpoint Determination, Research Design, Clinical Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The purpose of an exploratory clinical trial is to determine whether a new treatment is worth evaluating in subsequent trials. These trials often assessed the efficacy and safety of a single‐arm design with binary outcomes. In cancer therapy, time‐to‐event may be the primary endpoint. In such cases, the frequentist method is typically used to determine sample size. The Bayesian method has recently attracted attention from the perspective of using prior information and introducing early termination criteria. We propose a sample size determination method based on Bayesian power using the posterior probability and prior predictive probability of the hazard ratio (parameter), assuming that the survival functions of historical control and new treatment have proportional hazards. The prior information of the parameter is expressed as the analysis prior and the uncertainty of the parameter is expressed as the design prior. To conduct the clinical trial efficiently, we extended the study design to include early termination criteria. The simulation results showed that the sample size decreased when using an informative analysis prior, whereas it increased when using a design prior that accounted for variance, thus allowing for a more conservative sample size design while taking advantage of the available prior information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Biostatistics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
ORCID-Profile: Go Horiguchi
Zitieren
APA
Horiguchi, G., Yokota, I., & Teramukai, S. (2026). Bayesian Power‐Based Sample Size Determination for Single‐Arm Clinical Trials With Time‐to‐Event Endpoints. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70087
Vancouver
Horiguchi G, Yokota I, Teramukai S. Bayesian Power‐Based Sample Size Determination for Single‐Arm Clinical Trials With Time‐to‐Event Endpoints. Pharmaceutical Statistics. 2026. doi:10.1002/pst.70087
BibTeX
@article{Horiguchi2026,
author = {Horiguchi, Go and Yokota, Isao and Teramukai, Satoshi},
title = {Bayesian Power‐Based Sample Size Determination for Single‐Arm Clinical Trials With Time‐to‐Event Endpoints},
journal = {Pharmaceutical Statistics},
year = {2026},
doi = {10.1002/pst.70087}
}
EUVIMED